Health/Beauty/Medical
Gifts/Luggage/Sports equipment & Toys
Clothes/Textile/Components
Packages/Advertisements/Office equipment
Metallurgic/Chemical/Plastic products
Electrical/Communication/Components
Home & Garden/Lights/Construction/Protection
Electronic-Equipment/Household appliances
Autos/Traffic and Transportation equipment
Agricultural/Forestry and Food products.
Machines/Industrial components and Tools
TRAFEDIN
Shop info
- Lane 15, Ngoc Hoi - Giai Phong - Lane 15, Ngoc Hoi - Giai Phong - Hoang Mai - Hanoi
Traphaco
View shop PRESENTATION: Box of 3 blister x 10 film-coated tablets.
COMPOSITION: Each film coated tablet contains:
Nifedipin......................................................................................................10 mg
Excipients (PVP, Avicel 101, Lactose, Talc, Magnesium stearate, DST,
HPMC 606, PEG 6000, Titanium dioxyde, Quinolein lake)..................................q.s.
PHARMACOLOGY:
Pharmacodynamics:
Nifedipine is a dihydropyridine calcium channel blocking drug with effect selective inhibition of calcium ion flow by interaction with specific calcium channels in the cellular membrane. Nifedipine decreases the tension in smooth muscle in arterioles, which give a reduction of the peripheral resistance and thereby a decreases of arterial blood pressure. Regression of left ventricular hypertrophy has been registered during long term treatment of Nifedipine. Nifedipine dilates coronary blood vessels, which results in improved myocardial - blood flow and increases the oxygen tension in the heart and the heart work load is reduced by the marked reduction of the peripheral arterial resistance, reduce after load with effect against angina pectoris. Nifedipine counter acts and prevents digital vasospasm which leads to a reduce number of attacks in patients with both primary and secondary Raynaud's diseases. Nifedipine is relatively selective for the blood vessels, with far lower affect on heart muscle cells as compared to the smooth muscle surrouding the blood vessels, Nifedipine has therefore no direct effect on heart contractility and impulse - conductility when in normal clinical doses, little effect on cardiac output. Nifedipin has also natriuretic and diuretic but not kaliuretic effect, increase renal blood flow and the glomerular filtration rate.
Pharmacokinetics:
Nifedipine is rapidly and almost completely absorbed from the gastrointestinal tract, but undergoes extensive hepatic first pass metabolism, resulting in bioavailability after oral administration is 45 - 75%. Maximal plasma concentration is reached after 2 - 3 hours after intake 1 hour, the effect is maintained in 12 hours. The plasma half-life is estimated 6 - 11 hours. Simultaneous food intake leads to delayed, but not reduced absorption. In plasma, Nifedipine is bound to albumin 92 - 98%. The volume of distribution is estimated between 0.6 - 1.2 litres/kg body weight. Nifedipine is metabolized in the liver to three inactive metabolites. These metabolites are then excreted through the kidney and between 5 - 15% is excreted bile in the feces. Only less than 1% is excreted unchanged in the urine. Therefore decreased liver function decreases the nifedipine clearance and prolongs the elimination half-life.
INDICATIONS:
- Hypertension: mainly treatment or supportive therapy in all cases of hypertension.
- Coronary heart disease: in cases of prevention and long-term treatment of coronary heart disease (in particular coronary insufficiency, angina pectoris, myocardial infarction syndrome and coronary artery spasm). Treatment after myocardial infarction should be started after severe coronary symptoms for about 8 days, when the circulation has stabilized.
DOSAGE AND ADMINISTRATION:
* Dosage: as directed by your physician.
Depending on extent and body of patient that proper dose adjustment.
- Hypertension:
Treatment of individual hypertension or in combination therapy.
Normal: 1 tablet x 3 times daily.
If necessary dosage can be adjusted to 2 tablets x 3 times daily.
- Coronary heart disease:
Normal: 1 tablet x 3 times daily.
If necessary dosage can be adjusted to 2 tablets x 3 times daily.
Coronary spasm: 2 tablets x 4 times daily.
Maximum: 2 tablets x 6 times daily for a temporary period.
*Administration:
Long-term treatment: with a little water, outside of meals.
Treatment of angina pectoris: chewing and keeping under the tongue for a short time, drug will be rapidly absorbed.
If you take 2 tablets a time, two doses must be separated by at least 2 hours.
CONTRAINDICATIONS:
- Cardiogenic shock.
- Advanced aortic stenosis.
- Within 1 month of myocardial infraction.
- Unstable or acute attacks of angina.
- Porphyria.
- Pregnant or breast feeding women.
PRECAUTIONS:
- Withdraw of ischaemic pain occurs or existing pain worsens shortly after initiating treatment, patients must stop using drug.
- Poor cardiac reserve; heart failure or significantly impaired left ventricular function (heart failure deterioration observed), patients must stop using drug.
- Reduce dose in hepatic impairment, diabetes mellitus.
ADVERSE REACTIONS:
The adverse effects are most common early in treatment, and disappear gradually within a few weeks or after dose adjustment.
Common: headache, flush and heat sensation, dizziness, nausea, palpitation, tachycardia.
Less common: hypotension, aggravated angina pectoris or rash, urticaria.
Rare: allergic reactions, purpura, photodermatitis, dyspnoea, hyperglycemia, elevated liver enzymes, myalgia, arthralgia, confusion, nervousness, sleep disturbances, extrasystole, syncope, agranulocytosis (leucopenia).
Inform your physician of any unusual reactions while using the drug.
DRUG - DRUG INTERACTIONS:
- Beta-blockers: although Nifedipine is often used in combination with Beta-blockers and is usually well tolerated, but the risk of severe hypotension, exacerbation of angina, congestive heart failure, and arrhythmia may be increased, especially in patients with decreased heart function.
- Cimetidin: concurrent use of Nifedipine and Cimetidine may increase serum concentration and effects of Nifedipine, thus it may be necessary to reduce the dose of Nifedipine.
- Fentanyl: severe hypotension has occurred during surgery in patients receiving Nifedipine, a Beta-blocking agent, and Fentanyl concomitantly. The manufactures recommended temporarily withholding Nifedipine for at least 36 hours before surgery in which use of high-dose fentanyl contemplated, if patient's condition permits.
- Anti-epileptics: concurrent use of Nifedipine and Anti-epileptics such as Phenytoin, resulting in raise serum Phenytoin levels. Therefore Phenytoin effects and toxicity is increased
- Theophyllin: Nifedipine reduced the serum Theophyllin levels and does not make changes in the control of asthma when it was given with Theophyllin.
- Quinidin: concurrent use of Nifedipine and Quinidine, resulted in significantly reduced serum levels of Quinidine in some patients, but in other Quinidine concentrations were unchanged.
- Digoxin: Nifedipin increased serum Digoxin levels about 15 - 45% during concomitant therapy. Patients receiving the drug concomitantly should be monitored for signs and symptoms of Digoxin toxicity and dosage of Digoxin reduced if necessary.
- Alpha-blockers: Alpha-blockers, especially Prazosin may produce an increased hypotensive effect.
- Anti platelets: Nifedipin can inhibit platelet aggregation. This effect may be additive with other antiplatelet drugs such as Aspirin, Ticlodipine.
- Calcium-channel blockers: plasma concentration of Nifedipine and Ditiazem were increased, when concurrent of Nifedipine and Diltiazem. The effect was probably due to Nifedipine and Diltiazem metabolized by the same hepatic enzyme, thus it reduces metabolism to each other.
- Immunosuppressants: Cyclosporine reduces Nifedipine metabolism through competition for metabolizing enzyme Cytochrom P450.
- Rifampicin induces liver P450, thereby it reduces Nifedipine levels and increase anginal attacks.
- Anti-inflammatory nonsteroid drugs may antagonize the anti-hypertensive effect by inhibiting renal Prostaglandin synthesis or by causing sodium and fluid retention.
- Grapefruit juice: concomitant oral administration of grapefruit juice has been reported to increase bioavailability of the drug. The interaction between grapefruit juice and nifedipine appears to results from inhibition of Cytochrom P450 enzyme by some constituents in the juice.
- Alcohol: Alcohol may increase the bioavailability and inhibit metabolism of Nifedipine. As result, serum concentration and effects of Nifedipine are increased.
- In addtition, caution is advised when Nifedipine is used concurrently with some drugs below: Anticoagulants (Coumarin and Indandione derivative), Anticonvulsants (Hydantoin), Quinine, Salicylates, Sulfinpyrazone, Estrogens, Amphotericine B, Carbonic anhydrase inhibitions, Corticoids, Diuretics, Potassium-depleting,…
OVERDOSAGE:
- Slight overdose may increase heart rate. If overdose is appeared early, gastric lavage and monitoring in special rooms and symptomatic treatment is indicated.
- Severe overdose: Calcium gluconate should be given intravenously. Monitoring heart rate, conduction and cardiac output. If severe hypotension, it is treated with intravenous fluid of Noradrenaline in normal concentration and combined with Strophantiline IV if the patient has signs of heart failure; Digitalis may be indicated.
STORAGE: In a dry place, temperature below 300C, protect from light.
SHELF - LIFE: 36 months from manufacturing date.
INVESTMENT AND DEVELOPMENT
From 2000 to present
2017
.jpg)
2016
Traphaco holds General Meeting of Shareholders term of 2016-2020
Traphaco receives National Quality Gold Awards 2015
Traphaco among the top 40 valuable company brands and top 50 listed companies in Vietnam
Traphaco among Top 10 Prestigious Pharmaceutical Company of Vietnam 2016
Traphaco builds company strategy for 2017-2020
Traphaco continues to be selected as National Brand - Vietnam Value
2015
Traphaco was named among the Top 15 Brands of Vietnam 2014
Traphaco won the title “Star of Vietnamese medicine”
Traphaco was rated among Top 50 enterprises in Vietnam
Traphaco won the Top 10 well-known brands in Vietnam
2014
Traphaco CEO was honored as one of the Top 50 business leaders in 2013
Traphaco received the Certificate of Merit for the enterprise producing high quality goods 2014 (under the framework of the Vietnam High Quality Goods program)
Traphaco was named among the "Top 15 Famous Brands 2013"
2013
Traphaco won the prizes for the best international enterprise and the excellent manager of the European Business Association and other awards as follows:
Asia - Pacific International Quality Award 2013
ASEAN famous brand
Top 10 typical enterprises for social responsibility (Vietnam Gold Star Award)
Top 10 brands in Vietnam
2012
On October 29th 2012, TRAPHACO became a major shareholder of the Quang Tri Pharmaceutical - Medical Supplies JSC, holding 42.91% of charter capital.
On May 11th 2012, TRAPHACO officially became a major shareholder of the Dak Lak Pharmaceutical - Medical Supplies JSC with 24.5% of the charter capital. On October 10th 2012 TRAPHACO successful bought more shares of the Dak Lak Pharmaceutical - Medical Supplies JSC to increase its ownership ratio from 24.5% to 51%.
Traphaco founded 2 more branches in Quang Ninh, Gia Lai, bringing the total branches to 14 (2 branches of level 1, 12 branches of level 2)
In April 2012, TRAPHACO received the "International Quality Award" in Germany. In May 2012, TRAPHACO received the award for TOP 10 typical enterprises for the community. On June 19th 2012, TRAPHACO was presented the certification of "TOP 50 companies of the most efficient business in Vietnam." On October 4th2012, TRAPHACO received the Vietnamese President’s decision on the grant of the First Labour Medal to Traphaco.
2011
In November 2011 TRAPHACO successfully bought more shares of TRAPHACO Hi-tech JSC, raising its percentage of ownership in TRAPHACO CNC from 12.83% to 50.96%.
Traphaco founded 5 branches in Binh Thuan, Dong Nai, Quang Ngai, Can Tho, and Khanh Hoa.
TRAPHACO received the TOP 100 Vietnam Gold Star Award, especially the "TOP 10 typical enterprises for social responsibility" title.
TRAPHACO attended "The Annual Report 2010" poll and was awarded the "Best Annual Report". Along with this award, TRAPHACO was rated AAA for the 'Annual Report of Vietnam confidence index" for businesses operating efficiently, demonstrating transparency, financial strength, long-term growth prospects, control of capital and risk at the lowest level.
In June 2011, the program "building standards to identify Dioscorea hamiltonii as medicinal plant,” under the GreenPlan Project (Project to research and develop medicinal plants of TRAPHACO) received funding from the World Bank presented through the program "Vietnam Innovation Day 2011".
In April 2011 the project entitled "Research and produce Boganic liver tonic and detoxification medicine from medicinal plants of Vietnam" won the first prize of the Vietnam Fund for Technological Innovation (VIFOTEC).
2010
TRAPHACO was the only unit in Vietnam to receive the WIPO Award of the World Intellectual Property Organization. The company also won the third Prize for Social Responsibility in the Field of Environment (CSR), TOP 100 Vietnam Gold Star Award. Particularly, on December 10, TRAPHACO received the title of Labour Hero for its achievement in the 2000-2009 period.
2009
TRAPHACO was recognized as the most famous brand of the Vietnam pharmaceutical industry
Traphaco launched Traphaco Sapa Co., Ltd. in Lao Cai, holding 100% of capital.
2008
On November 26th 2008, Traphaco’s shares (code: TRA) were officially traded on the HCM City Stock Exchange (HOSE).
Traphaco won the Vietnam Gold Cup for Kindness.
2007
On November 27th TRAPHACO JSC celebrated its 35th anniversary and received the second-class Labor Medal presented by the President of the Socialist Republic of Vietnam. The President also presented the third-class Labor Medal for the company’s trade union. Experiencing 35 years of construction and development, TRAPHACO JSC really grew up and made great contributions to the protection of people’s health as well as the development of the pharmaceutical industry in Vietnam.
2000
In January 2000, the Transportation Pharmaceutical and Medical Equipment Company officially operated under the model of a joint stock company. On July 5th2001 the company changed its named into TRAPHACO, for the purpose of trading in multiple industries in line with the new economic trends. Its main business sectors include: Pharmaceuticals, medical materials, chemical, medical supplies and equipment, food, wine, beer, beverage, cosmetics, consulting service, scientific and technical services, transfer of technology in the field of pharmacy and export-import activities.
The period before equitization (1972 – 1999)
PHASEPERFORMANCE EQUITIZED
since 1972 to date
1999
The decision to equitize the Transportation Pharmaceutical and Medical Equipment Company was issued on September 27th 1999, with 45% of capital held by the state. The decision was made under the State policy of renewal, reform of State-owned enterprises to improve their business and operation. This was the most important moment. The company’s leaders and workers positively prepared all legal conditions for the meeting of the founding shareholders on November 15th 1999.
1994
The Transportation Pharmaceutical and Medical Equipment Company was founded on May 16th, 1994 (TRAPHACO) with functions of production and trading of pharmaceuticals, medical supplies and equipment. The company opened stores at 18A Le Duan Street, No. 9 Lang Ha, No. 31 Lang Ha Street, and set up a warehouse at No. 108 Thanh Cong Street, Hanoi to facilitate its business. By directly involving in the circulation and distribution of drugs, medical supplies and equipment, Traphaco could well grasp the needs of the market. The company later hired 6,000 m2 of land in Phuc Xa, Xuan La 1, Xuan La 2 and Phu Thuong in Hanoi to expand its operation.
1993
The Railway Pharmaceutical Enterprise was founded on June 1st 1993 (trade name RAPHACO) with the functions of manufacturing and trading medicines. The company had 80 employees, capital of VND150 million, rudimentary equipment, and narrow space (only 340 m2). The newly-established company faced a lot of difficulties, but with its courage and determination, the company overcame difficulties to step by step develop.
1981
The Railway Pharmaceutical Factory was established on May 28th 1981 by being upgraded from the Railway Medicine Production Group.
1977
For a period of time, as required by the situation, the railway medicine production group only distributed medicines. On August 31st 1977 its functions and tasks of producing medicines and distributing medicines to the entire railway sector was resumed. At that time the group has 37 members.
1972
The medicine production group of the Railway Health Department was founded on November 28th 1972, with 15 employees and the main task of making drugs under prescription. The group produced serum, fluids, distilled water serving hospitals of the railway sector during the war. The group was based at No. 75 Yen Ninh Street, Hanoi, the same place with the Railways Health Department.
VISION
Vision 2020 to become No. 1 Enterprise Vietnam Pharmaceutical industry in terms of revenue, profit and market capitalization.
MISSION
Our mission is to pioneer in the development of green pharmaceuticals to protect human health.
TRAPHACO SAPA SINGLE MEMBER LIMITED LIABILITIES COMPANY
- Headquarter: Section 9, Sapa Town, Sapa District, Lao Cao Province
- Chartered Capital: VND16,800,000,000
- TRAPHACO’s ownership: 100%
Main functions:
TRAPHACO Sapa specializes in the processing of ingredients and input
herbal ingredients as well as the researching of GACP for TRAPHACO.
At the same time, it serves as the center for developing farming areas
for herbal ingredients for TRAPHACO. The TRAPHACO SAPA factory
started in 1998 with an extraction assembly line, processing the input
herbal ingredients and with more than 4 ha of land for the test-farming
of medicinal herbs.
TRAPHACO HUNG YEN LIMITED LIABILITIES COMPANY
- Headquarter: Tan Quang Commune, Van Lam district, Hung Yen Province
- Chartered Capital: VND150,000,000,000
- TRAPHACO’s ownership: 100%
Main functions:
Manufactures medicines, pharmaceutical ingredients
and inputs.
DAK LAK PHARMACEUTICALS AND MEDICAL EQUIPMENTS JOINT STOCK COMPANY (BAMEPHARM)
- Headquarter: 9A Hung Vuong, Buon Ma Thuot City, Dak Lak province
- Chartered capital: VND19,415,880,000
- TRAPHACO’s ownership: 58%
Main functions:
Dak Lak Pharmaceutical and Medical Equipment joint stock company
has over 35 years of history, specializing in distributing pharmaceutical
products and medical equipment in the two provinces Dak Lak and Dak
Nong. In addition, the company has a sales network of 400 retail points
and 20 branches, locating in many townships and mountainous
communes in the region. Dak Lak Pharmaceuticals and Medical
Equipment joint stock company is a reputable brand to the people of
the Central Highland region. In line with the general trend of
development and integration, the company has opened a GPP-certified
pharmacy chain in the two provinces Dak Lak and Dak Nong to meet
the requirements of the Ministry of Health and the growing demand
of customers.
TRAPHACO HIGH-TECHNOLOGY JOINT STOCK COMPANY (TRAPHACO CNC)
- Headquarter: Tan Quang Commune, Van Lam district, Hung Yen Province
- Chartered Capital: VND94,703,570,000
- TRAPHACO’s ownership: 51%
Main functions:
TRAPHACO specializes in processing and manufacturing of
TRAPHACO’s products.The factory of TRAPHACO CNC, which is
located at Van Lam, Hung Yen, was first constructed in October
2004 and put into operation in January 2007. With over 10.000m2
of facilities and warehouses, the factory is comprised of 01 facility
producing compressed pills for traditional medicines, 01 facility
for preliminary processing, 01 tea processing facility, 01 facility
for tubed medicines and another one for powdered medicines.
The Van Lam Factory specializes in traditional medicines and
has been certified with GPs-WHO standards in 2008. It is the first,
largest and most technologically-advanced traditional medicine
manufacturing facility in Vietnam.
»» The message of the final year of the term, 2015 “Develop corporate culture”, focus on the theme: “Cooperate in work – Share benefits – Commit to targets – Honor all commitments” with the objective all individuals and departments in the entire Traphaco network understand the activities of the Company, united for an objective, cooperated to create synergized power, which will be the catapult to launch Traphaco into a strong growth trajectory in the coming term.
»» The emulation campaign attracted 100% of employees to participate: with 200 signed projects, 20 winners, total prize value of over VND1 billion. Many projects develivered great results for the Company. Among which, the first prize belong to the project “Apply KPI in the management of the enterprise”.
»» Activities in rallying the Company’s tradition day: Selected 20 most outstanding individual to be acknowledged and given a prize, which is a trip to visit Bali – Indonesia and Singapore; Organized many activities, sports and art shows with the intention to build corporate culture, enhance the cooperation between departments/individuals within the Company for example:
The contest “bonding to show talents”, the soccer tournament, the tennis championship to improve the morale of the employees and motivate them at work.
Company images
